EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Lessons learned from a decade of EUS(-FNA) staging in esophageal and GEJ carcinoma: towards a selective staging strategy

J S E Quik, J W van Sandick, E C Owers, A Bartels-Rutten, F E M Voncken, L L Kodach, T R de Wijkerslooth, J M van Dieren, J E G IJspeert

Diseases of the Esophagus · 2026-11-02 · 39 (6)

DOI: 10.1093/dote/doag128 ↗
AbstractBibliografische Angaben

Abstract

Abstract Endoscopic ultrasonography with fine-needle aspiration (EUS(-FNA)) is recommended by current guidelines as part of the staging for esophageal and gastro-esophageal junction (GEJ) carcinoma, yet its incremental value over modern 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) remains uncertain. This Lessons Learned article reflects on over a decade of EUS(-FNA) and FDG-PET staging in 402 patients with potentially curable esophageal or GEJ carcinoma at a high-volume tertiary referral center. In 91.3% of patients, EUS(-FNA) did not alter the radiation field as would have been defined by FDG-PET. EUS(-FNA) resulted in an expansion of the radiation field in 4.5% and reduction in 4.2% of patients. Squamous cell carcinoma showed more than two-fold greater likelihood of radiation field modification. Among 193 patients classified as FDG-PET non-suspicious for malignant lymph nodes (LNs), EUS-FNA identified malignant LNs in eight patients (4.1%), which influenced the radiation field. In 5 of 402 patients (1.2%) a malignant LN was detected with EUS-FNA in a station that would not have routinely been resected surgically. In patients planned for neoadjuvant or definitive chemoradiotherapy (CRT), LN staging is of direct therapeutic consequence: underestimation of nodal disease may result in geographic miss, while overestimation leads to unnecessary irradiation. In contrast, in patients treated with perioperative 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) followed by surgical lymphadenectomy, most involved LN stations are routinely addressed surgically, limiting the added value of EUS(-FNA) for treatment planning. Therefore, we view EUS(-FNA) as a selective staging tool in patients planned for neoadjuvant or definitive CRT, rather than a procedure applied routinely to all patients.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →